Asieris Pharmaceuticals

Diversified pharma

688176 · SSE STAR Market · China

Public Market Listing

688176SSE STAR Market

SSE STAR Market primary exchange listing

Live quotes, historical charts, and market capitalization for Asieris Pharmaceuticals are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
NepicastatNo recent activity
Phase 1
DBHSmall molecule
Inflammatory Bowel Disease
Ulcerative Colitis

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (12)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1$10M—$91M$16Mreport ↗
View 11 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q3$30M$24M$129M$36Mreport ↗
2025-H1$18M$16M$100M$22Mreport ↗
2024-Q3$19M$18M$68M$38Mreport ↗
2024-H1$11M—$161M$27Mreport ↗
2024-Q1$3.4M$9.5M$291M$12Mreport ↗
2023-Q3$0.4M$34M$226M$37Mreport ↗
2023-H1<$0.1M$26M$187M$27Mreport ↗
2023-Q1$0$8.3M$221M$9.2Mreport ↗
2022-Q3$0$25M$101M$24Mreport ↗
2022-H1$0$14M$113M$14Mreport ↗
2022-Q1$0$6.5M$90M$7.5Mreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$41M—$250M—report ↗

Asieris Pharmaceuticals reported 2025 revenue of $41M, up 46.2% YoY; the company’s own report cited operating revenue of RMB 277 million, up 37.49% YoY. Cash and equivalents were $250M (approximately RMB 1.692 billion), with R&D spend, net income, and quarterly burn not disclosed.

During 2025, the company advanced its Commercialization 2.0 strategy, and in March 2026 CEVIRA (APL-1702), the world’s first non-invasive treatment for precancerous cervical lesions, was approved in China. The EU marketing authorization application for CEVIRA is under review, and U.S. Phase III trial discussions are ongoing. Pipeline progress included APL-2302 Phase I/IIa clearance, APL-2401 regulatory approvals in China and Australia, APL-2501 IND plans for mid-2026, positive APL-1401 Phase Ib signals, and APL-1202 IND approval. The SYSTEM BLUE blue-light cystoscopy system also received market approval to work with Hexvix. No numeric guidance was provided, though management said 2026 is expected to mark an inflection point.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$28M$43M$86M$53Mreport ↗
2023-FY$1.9M$52M$245M$57Mreport ↗
2022-FY$0$36M$149M$37Mreport ↗
2021-FY$0$30M$410M$36Mreport ↗